Document Detail


Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels.
MedLine Citation:
PMID:  11268498     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Somatostatin is a naturally occurring hormone widely identified in a number of human tissues, with a broad spectrum of physiological actions. Octreotide is a synthetic analogue of somatostatin, which seems to be promising in clinical use. AIMS: a. to evaluate the efficacy of octreotide in pain control of patients with advanced gastrointestinal cancer, as well as octreotide's outcome in the hepatic function; b. to investigate the relationship between pain intensity and beta-endorphin blood levels in the patients. PATIENTS: The study group consisted of 25 patients (age range: 48-89 years, 14 males, 11 females) with far advanced gastrointestinal cancer. METHODS: All the patients were under s.c. morphine administration using a continuous infusion pump. When pain intensity increased, 0.6 mg/day of octreotide was added to the therapeutic regimen in the same syringe of the continuous infusion pump. Pain intensity and beta-endorphin blood levels were measured five times: Once before octreotide administration and the other four 12, 24, 48 hours and 7 days after. A complete blood count and a biochemical screening profile were taken before the administration of octreotide as well as on the 7th and the 14th day. RESULTS: 24 out of 25 cases showed a reduction in pain intensity (pretreatment x = 5.3, post-treatment x = 0.6). beta-endorphin blood levels increased significantly during the study (an increase of 184.78% was observed on the 7th treatment day). In one patient pain control was achieved by increasing morphine dosage. Statistically significant changes were observed in hepatic function indices (p < 0.02). Significant side-effects were not observed. CONCLUSION: Octreotide can be used as an adjuvant analgesic in the management of gastrointestinal cancer pain which is managed by continuous s.c. administration. Although fuither research needs to be done, octreotide's administration seemed to improve hepatic function of these patients, therefore, it could potentially have a positive effect in the patient's quality of life.
Authors:
S Befon; K Mystakidou; M Lyra; N Tubanakis; L Vlahos
Related Documents :
426198 - Lethal pancreatitis: a diagnostic dilemma.
20857518 - Clinical implications of accessory pancreatic duct.
16048498 - Dic secondary to acute pancreatitis.
6609418 - Functional recovery of the exocrine pancreas after acute pancreatitis.
1822448 - Luminol-dependent chemiluminiscence of monocytes and granulocytes in multiple sclerosis...
19585118 - Successful treatment of refractory cardiac tamponade due to rheumatoid arthritis using ...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  20     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2000 Sep-Oct
Date Detail:
Created Date:  2001-03-27     Completed Date:  2001-04-12     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  4039-46     Citation Subset:  IM    
Affiliation:
Pain Relief and Palliative Care Unit, Areteion Hospital, University of Athens, Vas. Sofias 76, 11528, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Analgesics / therapeutic use
Biological Markers / blood
Female
Gastrointestinal Agents / administration & dosage,  therapeutic use*
Gastrointestinal Neoplasms / physiopathology*
Humans
Infusions, Parenteral
Liver Function Tests
Male
Middle Aged
Octreotide / administration & dosage,  therapeutic use*
Pain / drug therapy*,  prevention & control
Pain Measurement
Time Factors
beta-Endorphin / blood*
Chemical
Reg. No./Substance:
0/Analgesics; 0/Biological Markers; 0/Gastrointestinal Agents; 60617-12-1/beta-Endorphin; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic significance of P53 histochemistry and DNA histogram parameters in head and neck malignan...
Next Document:  Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse e...